Livzon Monoclonal Antibody

Livzon Monoclonal Antibody is a biopharmaceutical company based in Zhuhai, China, specializing in the development and commercialization of monoclonal antibodies and recombinant protein therapeutics. As a key subsidiary of Livzon Pharmaceutical Group, the company focuses on high-growth therapeutic areas including oncology, immunology, and infectious diseases. Their commercial portfolio features several approved biosimilars, such as Anshida (infliximab) and Anruize (tocilizumab), alongside the V-01 recombinant fusion protein vaccine for COVID-19. The company operates advanced R&D centers and large-scale GMP-compliant manufacturing facilities to support its integrated biologics platform. With a robust pipeline of innovative antibodies and biosimilars, Livzon Monoclonal Antibody is a significant player in the Chinese biologics market.